Drug Trial Radar · NCT00411645
Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
Last checked: Nov 19, 2026Latest source record: Jun 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
681
Actual
Start
Dec 13, 2006
Primary completion
Nov 10, 2008
Study completion May 23, 2009
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Dec 14, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research study is to investigate whether or not maribavir is safe and effective for preventing CMV disease when taken by mouth for up to 12 weeks in patients who have had a stem cell transplant.
Conditions
- Cytomegalovirus Infections
Interventions
maribavirDrug
100 mg twice daily for up to 12 weeks
placeboOther
twice daily for up to 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Endpoint Committee (EC)-Confirmed Cytomegalovirus (CMV) Disease Within 6 Months Post-TransplantationTime frame: 6 months post-transplant
Locations
97 sites in 9 countries. Site status is shown where the registry gives one.
University of Arkansas Myeloma Institute
Little Rock, Arkansas
City of Hope Medical Center
Duarte, California
Scripps Green Hospital
La Jolla, California
UCSD Moores Center
La Jolla, California
UCLA Medical Center
Los Angeles, California
University of California, San Francisco
San Francisco, California
Stanford University Medical Center
Stanford, California
Rocky Mountain Cancer Center
Denver, Colorado
Shands Hospital
Gainesville, Florida
H. Lee Moffitt Cancer Center
Tampa, Florida
Emory University
Atlanta, Georgia
Northwestern University Medical Center
Chicago, Illinois
University of Chicago
Chicago, Illinois
Loyola University
Maywood, Illinois
St Francis Hospital
Beech Grove, Indiana
University of Iowa Hospitals and Clinics
Iowa City, Iowa
University of Kentucky Chandler Medical Center
Lexington, Kentucky
University Medical Center University of Louisville Hospital
Louisville, Kentucky
Greenbaum Cancer Center
Baltimore, Maryland
Massachusettes General
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Wayne State Medical Center
Detroit, Michigan
Henry Ford Health System
Detroit, Michigan
University of Minnesota
Minneapolis, Minnesota
Mayo Clinic College of Medicine
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
Hackensack University Medical Center
Hackensack, New Jersey
Roswell Park Cancer Institute
Buffalo, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
New York Presbyterian Hospital,Weill Cornell Medical Center
New York, New York
Mount Sinai Hospital
New York, New York
University of Rochester Medical Center
Rochester, New York
University of North Carolina Hospital
Chapel Hill, North Carolina
Duke Medical Center
Durham, North Carolina
Wake Forest Medical Center
Winston-Salem, North Carolina
The Jewish Hospital
Cincinnati, Ohio
Ireland Cancer Center Case Western Reserve University
Cleveland, Ohio
University of Oklahoma
Oklahoma City, Oklahoma
Showing 40 of 97 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.